In:
Cardiology, S. Karger AG, Vol. 138, No. 2 ( 2017), p. 91-96
Kurzfassung:
〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 MicroRNA are noncoding RNA that have a significant role in both inflammatory and cardiovascular diseases. 〈 b 〉 〈 i 〉 Aims: 〈 /i 〉 〈 /b 〉 We aimed to assess whether the inflammation-related microRNA-155 is associated with the development of adverse left ventricular (LV) remodeling following ST elevation myocardial infarction (STEMI). 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 Peripheral blood samples were collected in the inflammatory (day 2), proliferative (day 5), and maturation phases (6 months) after STEMI ( 〈 i 〉 n 〈 /i 〉 = 20). Granulocytes, monocytes, and lymphocytes were enumerated with flow cytometry. The changes in LV volumes were assessed with 3-D echocardiography on day 1 and after 6 months. Adverse remodeling was defined as a 〉 20% increase in end-diastolic volume. Healthy subjects were recruited as controls. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 MicroRNA-155 measured on day 5 correlated positively with the relative change in end-diastolic volume ( & #x03C1; = 0.490, 〈 i 〉 p 〈 /i 〉 = 0.028). MicroRNA-155 (day 5) was significantly higher in patients with compared to patients without adverse LV remodeling. The expression level was similar in healthy subjects ( 〈 i 〉 n 〈 /i 〉 = 8) and in patients with LV remodeling. There was a positive correlation between microRNA-155 and the amount of monocytes (day 5, & #x03C1; = 0.463, 〈 i 〉 p 〈 /i 〉 = 0.046). 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 Impaired downregulation of microRNA-155 during the second phase of the post- STEMI inflammatory response is a determinant of the development of adverse LV remodeling.
Materialart:
Online-Ressource
ISSN:
0008-6312
,
1421-9751
Sprache:
Englisch
Verlag:
S. Karger AG
Publikationsdatum:
2017
ZDB Id:
1482041-9
